Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia

Hairy cell leukemia

Encorafenib Plus Binimetinib for People With BRAF V600E Mutated Relapsed/Refractory HCL Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia Title: Moxetumomab Pasudotox-tdfk (Lumoxiti ) and Rituximab (Rituxan ) for Relapsed Hairy Cell Leukemia Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia Rituximab in Hairy Cell Leukemia: a Multicenter Retrospective Study Therapy Optimisation for the Treatment of Hairy Cell Leukemia